KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash & Current Investments: 2010-2025

Historic Cash & Current Investments for TherapeuticsMD (TXMD) over the last 11 years, with Sep 2025 value amounting to $7.1 million.

  • TherapeuticsMD's Cash & Current Investments rose 40.97% to $7.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 26.63%. This contributed to the annual value of $5.1 million for FY2024, which is 16.92% up from last year.
  • Latest data reveals that TherapeuticsMD reported Cash & Current Investments of $7.1 million as of Q3 2025, which was up 17.24% from $6.1 million recorded in Q2 2025.
  • Over the past 5 years, TherapeuticsMD's Cash & Current Investments peaked at $137.6 million during Q1 2021, and registered a low of $4.3 million during Q4 2023.
  • Moreover, its 3-year median value for Cash & Current Investments was $5.7 million (2025), whereas its average is $7.6 million.
  • As far as peak fluctuations go, TherapeuticsMD's Cash & Current Investments tumbled by 92.86% in 2023, and later skyrocketed by 40.97% in 2025.
  • TherapeuticsMD's Cash & Current Investments (Quarterly) stood at $64.9 million in 2021, then fell by 6.69% to $60.6 million in 2022, then plummeted by 92.86% to $4.3 million in 2023, then rose by 16.92% to $5.1 million in 2024, then skyrocketed by 40.97% to $7.1 million in 2025.
  • Its Cash & Current Investments stands at $7.1 million for Q3 2025, versus $6.1 million for Q2 2025 and $5.7 million for Q1 2025.